58 results about "Receptor subunit" patented technology

Provided are compositions and method for prophylaxis and / or therapy of hearing loss or related dysfunctions, including but not limited to tinnitus, that could be ameliorated by restoring central nervous system inhibitory synapses. The compositions include polynucleotides and viral vectors that are used to express at least one GABA receptor component which may be a GABAA receptor alpha 1 subunit or GABAR receptor Ib subunit. Expression of the GABA receptor may be under control of a CaMKII promoter.

The present application discloses an IL-2 derivative, by introducing at least one cysteine residue on the basis of wild type IL-2, partially or completely closing the binding plane of the IL-2 derivative with the alpha receptor subunit, while basically retaining the affinity to the beta and gamma receptor subunit complex.

The invention belongs to the technical field of in-vitro diagnosis and anesthesia monitoring. The invention discloses a serum protein marker combination for evaluating anesthesia depth and application of the serum protein marker combination. The composition is composed of orexin, S100 calcium binding protein B, C reactive protein and gamma-aminobutyric acid A type receptor alpha1 subunit, and can synergistically reflect the anesthesia sedation state from multiple dimensions. The invention also provides a detection kit containing the marker and application of the detection kit in evaluation of anesthesia depth. The combination has the advantages of being high in accuracy, objective, stable and easy to detect, can serve as an effective supplementary tool of an existing nerve electrophysiology monitoring technology, and provides a new reference means for intraoperative sedation depth monitoring and precise anesthesia management.

Provided are antibodies and antigen binding fragments thereof that bind to human interleukin-11 receptor subunit α (IL-11Rα) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers, inflammatory diseases, autoimmune diseases, and others.

Disclosed is a polypeptide dimeric protein containing two monomers, each of which contains an extracellular domain (FcεRIa-ECD) of an alpha subunit of an IgE Fc receptor. The dimeric protein has advantages that an excellent binding ability to IgE is exhibited as compared with a conventional therapeutic agent containing an anti-IgE antibody, and less other side effects are exhibited due to lack of ADCC and CDC functions. Thus, the dimeric protein can be applied to a medical product for treating or preventing an IgE-mediated allergic disease.

The present invention belongs to the field of medicinal chemistry technology, specifically relating to GluA2 AMPAR endocytosis-blocking transmembrane cyclic peptides and their applications. The present invention is based on the nine active amino acid sequence (GluA2-3Y) at the end of the AMPA receptor GluA2 subunit, undergoing structural modification and engineering. A hydrophobic group is attached to the N-terminus of the peptide, and amino acids at different positions in the peptide sequence are replaced with two cysteines according to a specific pattern. The sulfhydryl groups on the cysteines are then linked using a chemical linker to partially cyclicize the peptide sequence, thereby stabilizing the peptide sequence conformation, enhancing the transmembrane ability of the modified peptide, and improving the stability of the peptide sequence.

The present invention provides compounds of formula (I) and / or salts thereof and / or biologically active metabolites thereof and / or prodrugs thereof and / or solvates thereof and / or hydrates thereof and / or polymorphs thereof having affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 and act as GABAA α5 positive allosteric modulators, thereby useful in the treatment or prevention of diseases related to the GABAA α5 receptor, process for the preparation and intermediates of the preparation process thereof, pharmaceutical compositions comprising them alone or in combination with one or more other active ingredients and their use as medicaments.

The present invention provides compounds of formula (I) and / or salt thereof and / or biologically active metabolite thereof and / or prodrug thereof and / or solvate thereof and / or hydrate thereof and / or polymorph thereof having affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 and act as GABAA α5 negative allosteric modulators, thereby useful in the treatment or prevention of diseases related to the GABAA α5 receptor, process for the preparation and intermediates of the preparation process thereof, pharmaceutical compositions comprising them alone or in combination with one or more other active ingredients and their use as medicaments.

Provided are binding molecules with at least one interleukin-31 (IL-31) receptor subunit alpha-antigen-binding domain (IL-31RA-antigen-bindingdomain)capable of inhibiting IL-31activity,compositions of such binding molecules for treating IL-31-mediated disorders, uses of such binding molecules as medicaments for treating IL-31-mediated disorders, and methods of treating IL-31-mediated disorders using such binding molecules.Also provided herein are binding molecules with an IL-31RA-antigen-binding domain capable of inhibiting IL-31 activity and an IL-13-antigen binding domain capable of inhibiting IL-13activity, compositions of such binding molecules for treating IL-31-mediated disorders and / or IL-13-mediated disorders,uses of such binding molecules as medicaments for treating IL-31-mediated disorders and / or IL-13-mediateddisorders, and methods of treating IL-31-mediated disorders and / or IL-13-mediated disorders using such binding molecules.

The present application relates to the technical fields of biological medicine and cellular immunotherapy, and particularly relates to a signal conversion receptor targeting IL-10, an engineered macrophage and application thereof. The signal conversion receptor is composed of an extracellular domain and a transmembrane domain and an intracellular domain derived from TLR9, and the extracellular domain sequentially comprises a signal peptide, a HA tag and a specific binding domain of an IL-10 receptor alpha subunit from N-terminal to C-terminal. The present application further prepares an engineered macrophage SR CAR-M capable of specifically recognizing IL-10 and converting it into a TLR9 activation signal, which can induce macrophages to polarize to M1 type and has excellent phagocytosis and killing capacity for bladder cancer, breast cancer, lung cancer and melanoma cells, and can be used for preparing related tumor treatment drugs, overcoming the common problems of existing cell therapy, such as easy exhaustion, difficult infiltration and easy inhibition in solid tumors, and having significant clinical transformation potential.

The present invention provides a polypeptide dimeric protein containing two monomers, each of which contains an extracellular domain (FcεRIa-ECD) of an alpha subunit of an IgE Fc receptor. The dimeric protein according to the present invention has advantages that an excellent binding ability to IgE is exhibited as compared with a conventional therapeutic agent containing an anti-IgE antibody, and less other side effects are exhibited due to lack of ADCC and CDC functions. Thus, the dimeric protein can be applied to a medical product for treating or preventing an IgE-mediated allergic disease.

An HSV vector comprising an expression cassette for one or more of IL12, IL15, and hIL15Receptor alpha subunit is provided.

The present disclosure provides a population of genetically modified immune cells and uses thereof, the modified immune cells comprising (i) a chimeric antigen receptor (CAR) targeting a target protein on a target cell; (ii) a first immunomodulatory fusion protein comprising an ectodomain derived from a protein of tumor necrosis factor (TNF) superfamily, and an endodomain derived from a costimulatory molecule of a TNF receptor superfamily protein; (iii) a second immunomodulatory fusion protein comprising an ectodomain derived from a protein of TNF receptor superfamily, and an endodomain derived from a common g-chain cytokine receptor; and (iv) a third immunomodulatory fusion protein comprising an ectodomain derived from the same TNF receptor superfamily protein as in the second immunomodulatory fusion protein, and an endodomain derived from an a or b receptor subunit of the common g-chain cytokine receptor family.

A series of subunit selective allosteric modulators of NMDA receptor function according to Formula (I) is provided herein. Also provided is a method of treating neurological disorders such as Alzheimer's disease Parkinson's disease, schizophrenia, depression, stroke, psychosis and the like using compounds of Formula (I), optionally in combination with one or more further active agent. Pharmaceutical compositions containing a compound of Formula (I) and optionally one or more active agent for treating such disorders may be provided in the form of a tablet, capsule, pill, gel, granules, aerosol, aqueous buffer or a nanoparticle formulation, emulsion, liposome, etc.

The present invention provides compounds of formula (I) and / or salt thereof and / or geometric isomer thereof and / or stereoisomer thereof and / or enantiomer thereof and / or racemate thereof and / or diastereomer thereof and / or biologically active metabolite thereof and / or prodrug thereof and / or solvate thereof and / or hydrate thereof and / or polymorph thereof having affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 and act as GABAA α5 negative allosteric modulators, thereby useful in the treatment or prevention of diseases related to the GABAA α5 receptor, process for the preparation thereof, pharmaceutical compositions comprising them alone or in combination with one or more other active ingredients and their use as medicaments.

Provided are antibodies and antigen binding fragments thereof that bind to human interleukin-11 receptor subunit α (IL-11Rα) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers, inflammatory diseases, autoimmune diseases, and others.

The present invention provides methods of treating thyroid eye disease (TED) by administering an antibody, or and an antigen-binding fragment thereof, that binds to human interleukin-11 receptor subunit alpha (IL-11R alpha).

Methods for treating thyroid eye disease (TED) are provided by administering an antibody or antigen-binding fragment thereof that binds to human interleukin-11 receptor subunit alpha (IL-11Rα).

Provided are binding molecules comprising at least one interleukin-31 (IL-31) receptor subunit alpha-antigen-binding domain (IL-31RA-antigen-binding domain) capable of inhibiting IL-31 activity and uses of such binding molecules as medicaments for treating IL-31-mediated disorders. Also provided herein are binding molecules with an IL-31RA-antigen-binding domain capable of inhibiting IL-31 activity, and an IL-31RA-antigen-binding domain capable of inhibiting IL-13 activity, as well as uses of such binding molecules as medicaments for treating IL-31-mediated disorders and / or IL-13-mediated disorders.

The invention discloses application of a signal sequence receptor subunit delta gene SSR4 as a drug target in development of lung adenocarcinoma treatment drugs. The invention further discloses an RNAi molecule for inhibiting the SSR4 gene to treat lung adenocarcinoma. The RNAi molecule is a shRNA molecule with a target sequence selected from SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 and SEQ ID NO: 10. The shRNA molecule disclosed by the invention can be used for preparing a medicine for treating lung adenocarcinoma.

The application belongs to the field of biomedical technology, and aims to solve the problems of lack of metabolic typing characteristics in the current ESCC molecular typing method, lack of esophageal squamous cell carcinoma molecular typing method based on proteomics and metabolomics, and provides an esophageal squamous carcinoma ESCC molecular typing marker based on DIA proteomics and non-targeted metabolomics and its application. The marker is a combination of 4 proteins and 2 metabolites, the 4 proteins are: hexokinase 3 (HK3), Sec1 family domain protein 1 (SCFD1), septin 5 (SEPTIN5), and signal sequence receptor alpha subunit (SSR1); the 2 metabolites are creatine and 2-deoxy-D-glucose (2'DG). The application fills the gap of the molecular typing method based on proteomics and metabolomics in the field of esophageal squamous carcinoma research, and the proposed molecular typing model can be used as a method for diagnosis, treatment and prognosis evaluation of esophageal squamous carcinoma patients.

Described herein are the design and production of antibodies and antigen-binding fragments (e.g., chimeric and humanized antibodies) that specifically bind and inhibit activation of human common gamma chain (gamma c) (shared signaling receptor subunits used by six gamma c cytokines). Methods of production and functional assays that assess the efficacy of the produced antibodies are also described, along with the results that such anti-gammac antibodies are indicated for use in the treatment or prevention of autoimmune cases mediated by gammac or gammac cytokines, such as GVHD.

Engineered synthetic signal transduction molecules, referred to herein as "trikines," are provided. A trikine is a trispecific ligand of genetically engineered cell surface receptors, wherein the trikine specifically binds with high affinity to the extracellular domains of three different cell surface receptor polypeptides. In some embodiments, receptor multimerization resulting from binding to a trikine leads to intracellular transphosphorylation of the receptor subunits. In some embodiments, a trikine modulates STAT signal transduction resulting from receptor binding and multimerization.

Provided herein is a method of treating a subject for a glioblastoma, the method comprising: administering to the subject an immune cell genetically modified with: (a) a nucleic acid sequence encoding a binding triggered transcriptional switch (BTTS) that binds to a priming antigen that is tissue-specifically expressed in the central nervous system; (b) a nucleic acid sequence encoding a tandem chimeric antigen receptor (CAR) or T cell receptor (TCR) that has a first binding domain that recognizes Ephrin type-A receptor 2 (EphA2) and a second binding domain that recognizes Interleukin-13 receptor subunit alpha-2 (IL13RA2); and (c) a regulatory sequence operably linked to (b) that is responsive to the BTTS, wherein binding of the BTTS to the priming antigen activates expression of the tandem CAR or TCR, which binds EphA2 and / or IL13RA2 in the glioblastoma and induces killing of glioblastoma cells.

The present invention relates to a synthetic cytokine from the IL-6 family. The synthetic cytokine is a polypeptide comprising two binding sites from the same cytokine of the IL-6 family and a third binding site from an additional cytokine of the IL-6 family, wherein the additional cytokine does not require a cytokine-specific non-signaling alpha receptor subunit as part of the receptor complex to trigger signal transduction. All three binding sites of the polypeptide of the present invention must bind to their specific partners to trigger signal transduction. The present invention further relates to a polypeptide for use in medical applications, preferably for the prevention and / or treatment of conditions selected from the group consisting of lymphopenia, muscle atrophy, osteoporosis, thrombocytopenia, obesity-related metabolic disorders such as type II diabetes, obesity, insulin resistance, impaired glucose tolerance, dyslipidemia, hypertension, stroke, or cardiovascular disease, neurological disorders such as paraplegia, Alzheimer's disease, and Parkinson's disease.

The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that bind to IL-4 receptor subunit alpha (IL-4Rα). The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating inflammatory conditions (e.g., atopic dermatitis).

The invention relates to the technical field of biology, in particular to an IL-2 mutant and a construction method and application thereof, and the IL-2 mutant comprises a mutation site for enhancing IL-2R alpha binding and a mutation site for weakening IL-2R beta / gamma binding. The mutation site for enhancing IL-2R alpha binding comprises 1, 2, 3, 4, 5, 6, 7, 8 or 9 mutation sites selected from the group consisting of T37R, V69Y, E68Q, N71W, Y107D, M104F, L66G, E60H and L63W; the mutation site for weakening IL-2R beta / gamma binding comprises 1, 2, 3, 4 or 5 mutation sites selected from the group consisting of H16D, N88L, Q126V, L18E and Q126L. According to the application, the IL-2 antagonist is designed, the binding affinity of the IL-2 antagonist to IL-2R alpha is enhanced, and meanwhile, the binding affinity to IL-2R beta and IL-2R gamma is reduced, so that the proliferation of Tregs is inhibited, the anti-tumor immune response is enhanced, and the systemic toxicity and immunogenicity are reduced. According to the application, a molecular dynamics simulation and calculation method is also utilized to accurately identify and regulate the binding affinity of IL-2 and different receptor subunits, an IL-2 antagonist with multi-target specific binding is designed, and accurate regulation of an IL-2 signal channel is realized.

Provided herein are proteins that include a Vascular Endothelial Growth Factor A (VEGF-A) protein binding domain; proteins that include an Epstein-Barr Virus BCL-2 homolog (BHRF1) protein binding domain; proteins that include a Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) RBD protein binding domain; proteins that include an Interleukin-7 receptor subunit alpha (IL7R-α) protein binding domain; proteins that include a Programmed death-ligand 1 (PD-L1) protein binding domain; proteins that include a Tropomyosin-receptor kinase A (Trk-A) protein binding domain; and proteins that include an Interleukin-17 (IL-17A) protein binding domain.